Search

Systemic Levels of Anti-VEGF: What Available Data Reveal

Robert Avery MD, PhD

Show Description +

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Keywords:

Age-Related Macular Degeneration (AMD)

•

Age-Related Macular Degeneration (AMD)

•

Anti-VEGF

•

Bevacizumab

•

Diabetic macular edema, DME

•

Ranibizumab

•

Retina

Up Next

[2019] Amniotic Membrane Placement for Repair of Recurrent Macular Hole

[2019] Amniotic Membrane Placement for Repair of Recurrent Macular Hole

Stanislao Rizzo, MD

Pinhole Effect in Double Peel for Macular Hole

Pinhole Effect in Double Peel for Macular Hole

Hudson de Carvalho Nakamura, MD

Triple Procedure With Chronic Macular Hole, Subluxated IOL, and Retinal Detachment

Triple Procedure With Chronic Macular Hole, Subluxated IOL, and Retinal Detachment

Frederic Aissani, MD

Macular Hole Surgery: Retinal Massager

Macular Hole Surgery: Retinal Massager

Manish Nagpal, MS, DO, FRCS(UK)

Iatrogenic Macular Hole After TPA Injection for Submacular Hemorrhage

Iatrogenic Macular Hole After TPA Injection for Submacular Hemorrhage

Frederic Aissani, MD

The Big Mac: ILM Technique for Large Macular Holes

The Big Mac: ILM Technique for Large Macular Holes

Hudson Nakamura, MD

ILM Peel for Macular Hole Under Liquid PFC

ILM Peel for Macular Hole Under Liquid PFC

Hudson Nakamura, MD

My Peeling Technique for a Dense Plaque on the Posterior Capsule

My Peeling Technique for a Dense Plaque on the Posterior Capsule

Ashraf Armia, FRCSG, FACS

Experience a New Dimension: How Eyetube3D Works!

Experience a New Dimension: How Eyetube3D Works!

25-Gauge Vitrectomy for Retained Lens Fragments

25-Gauge Vitrectomy for Retained Lens Fragments

Yoreh Barak, MD, Lana Rifkin, MD, Omar Saleh, MD, Shlomit Schaal, MD, PhD

Systemic Levels of Anti-VEGF: What Available Data Reveal

Robert Avery MD, PhD

Robert L. Avery, MD, discusses the recent finding from CATT, IVAN on systemic concentrations of bevacizumab and ranibizumab after injection, the EPAR report in regard to the systemic safety of aflibercept, and his own study on serum levels of anti-VEGF drug levels (bevacizumab, ranibizumab, and aflibercept) and free VEGF in human plasma.

Posted: 1/16/2014

Keywords:

Age-Related Macular Degeneration (AMD)

•

Age-Related Macular Degeneration (AMD)

•

Anti-VEGF

•

Bevacizumab

•

Diabetic macular edema, DME

•

Ranibizumab

•

Retina

Please log in to leave a comment.

Comments

majid kheirkhahr

12 years ago

amazing.

More in Retina

Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR

Racial/Ethnic Disparities in TDR, DME, and Other Vision Threats in Patients With DR

Jordan Deaner, MD; Rehan Hussain, MD; and Vaidehi Dedania, MD

Managing Endophthalmitis: Tap-and-Inject or Immediate Vitrectomy?

Managing Endophthalmitis: Tap-and-Inject or Immediate Vitrectomy?

Samir N. Patel, MD and Maria H. Berrocal, MD

Emily Y. Chew, MD, the 2025 Lifetime Achievement Awardee

Emily Y. Chew, MD, the 2025 Lifetime Achievement Awardee

Emily Y. Chew, MD and R.V. Paul Chan, MD, MSc, MBA

The Business of Retina at VBS

The Business of Retina at VBS

Esther L. Kim, MD and Basil K. Williams Jr, MD